Novartis announced that full results from the Phase IIIb ARGON study were published online in Respiratory Medicine .. These results show that once-daily treatment with single inhaler, high-… read more.
Gilead Sciences and Galapagos announced Week 52 results from the Phase III FINCH 1 and FINCH 3 studies of GLPG 0634 (filgotinib), an investigational, oral, selective JAK1 inhibitor,… read more.
Roche announcedy that the FDA has issued an Emergency Use Authorisation (EUA) for the Elecsys IL-6 test. This test measures levels of the biomarker interleukin 6 (IL-6) and… read more.
Novartis announced that full results from the Phase IIIb ARGON study were published online in Respiratory Medicine .. These results show that once-daily treatment with single inhaler, high-… read more.
Aurinia Pharmaceuticals Inc. announced that new subgroup analyses from the completed AURORA pivotal trial of voclosporin were presented at the European League Against Rheumatism (EULAR) 2020 E-Congress in… read more.
Inovio , the International Vaccine Institute (IVI), and Seoul National University Hospital announced a partnership to start a Phase 1/II clinical trial of INOVIO’s COVID-19 vaccine INO 4800… read more.
A University of Minnesota trial with results published in the New England Journal of Medicine, goes the furthest in answering the question of whether a decades-old, repurposed hydroxychloroquine… read more.
Novartis, announced the full 52-week results from the Phase III PREVENT trial, which reinforce the substantial and sustained benefits of Cosentyx (secukinumab) across the axial spondyloarthritis (axSpA) spectrum… read more.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission (EC) has granted marketing authorisation for Darzalex (daratumumab) subcutaneous (SC) formulation for the treatment of… read more.
Pfizer Inc. announced that JAMA Dermatology has published complete results from the second Phase III monotherapy pivotal study (JADE MONO-2) of PF 04965842 (abrocitinib), an investigational oral once-daily… read more.
Shield Therapeutics plc with its lead product Feraccru/Accrufer (ferric maltol), notes the recent publication of two papers concerning Feraccru/Accrufer.ORal IrON supplementation with ferric maltol in patients with Pulmonary… read more.
Eli Lilly shared new results from a subgroup analysis of the Phase IIIb/IV, 52-week SPIRIT-Head-to-Head (SPIRIT-H2H) study of Taltz (ixekizumab) versus Humira (adalimumab) in biologic-naïve patients with active… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
